QURE - QURE has partnered with Chiesi in the EU for launch of Glybera, receiving a 20-30% net royalty rate. Analysts expect Glybera sales to reach up to $125 million by 2020, just in the EU. The EU has granted orphan drug exclusivity for Glybera for treatment of LPLD until October 2022.
In the US, they are moving toward US approval with additional trails, and expectations that the company launches the drug on its own by 2019. Sales in the US are expected to be similar to the EU. QURE expects to submit an IND filing for Glybera in the US in 1H14.
But I think QURE's value goes beyond just their treatment for LPLD. The company has a strong portfolio of gene therapy programs and will continue expanding its pipeline. Analysts mention that the Hemophilia B gene therapy could be a game changer as it offers the potential to eliminate the need for routine Factor IX replacement. Additional clinical stage pipeline programs include therapies for Porphyria,Sanfillipo B, and Parkinson's disease. QURE will likely add pipeline programs in the coming months/years.
They should be able to get through 2016 - 2017 before they need to raise cash again.
I think for the price, QURE represents an opportunity.
News 
Market Data 
Discover 
